Bulk Manufacturer of Controlled Substances Application: National Center for Natural Products Research NIDA MPROJECT, 48566 [2020-17433]
Download as PDF
<![CDATA[
48566
Federal Register / Vol. 85, No. 155 / Tuesday, August 11, 2020 / Notices
M.D., 76 FR 71,371 (2011), pet. for rev.
denied, 481 F. App’x 826 (4th Cir.
2012); Frederick Marsh Blanton, M.D.,
43 FR 27,616, 27,617 (1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined the term ‘‘practitioner’’ to mean
‘‘a physician . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . . , to distribute,
dispense, . . . [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess state authority in order to be
deemed a practitioner under the CSA,
DEA has held repeatedly that revocation
of a practitioner’s registration is the
appropriate sanction whenever he is no
longer authorized to dispense controlled
substances under the laws of the state in
which he practices. See, e.g., James L.
Hooper, M.D., 76 FR at 71,371–72;
Sheran Arden Yeates, M.D., 71 FR
39,130, 39,131 (2006); Dominick A.
Ricci, M.D., 58 FR 51,104, 51,105 (1993);
Bobby Watts, M.D., 53 FR 11,919, 11,920
(1988); Frederick Marsh Blanton, M.D.,
43 FR at 27,617.
According to New Mexico statute, ‘‘A
person who . . . dispenses a controlled
substance or who proposes to engage in
the . . . dispensing of a controlled
substance shall obtain a registration
issued by the board in accordance with
its regulations.’’ N.M. Stat. Ann. § 30–
31–12(A) (West, current with 2020
Regular Session laws in effect through
May 20, 2020). In turn, ‘‘dispense’’
means ‘‘to deliver a controlled
substance to an ultimate user . . .
pursuant to the lawful order of a
practitioner.’’ N.M. Stat. Ann. § 30–31–
2(H) (West, current with 2020 Regular
Session laws in effect through May 20,
2020). Further, ‘‘practitioner’’ means a
‘‘physician . . . licensed or certified to
prescribe and administer drugs that are
subject to the Controlled Substances
Act.’’ N.M. Stat. Ann. § 30–31–2(S)
(West, current with 2020 Regular
Session laws in effect through May 20,
2020).
Here, the undisputed evidence in the
record is that Registrant’s license to
practice medicine is revoked. As such,
he is not a ‘‘practitioner,’’ a physician
licensed or certified to prescribe a
controlled substance according to New
VerDate Sep<11>2014
17:02 Aug 10, 2020
Jkt 250001
Mexico law. Further, under New Mexico
law, a person who dispenses a
controlled substance in New Mexico
must be registered. The undisputed
record evidence is that Registrant’s New
Mexico controlled substance license is
expired.
For all of these reasons, Registrant
lacks authority to practice medicine and
prescribe controlled substances in New
Mexico. Accordingly, I will order that
Registrant’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. FB0178194 issued to
Mark D. Beale, M.D. This Order is
effective September 10, 2020.
Timothy J. Shea,
Acting Administrator.
[FR Doc. 2020–17448 Filed 8–10–20; 8:45 am]
BILLING CODE 4410–09–P
Controlled substance
Marijuana .......................
Tetrahydrocannabinols ..
Drug
code
7360
7370
Schedule
I
I
The company plans to bulk
manufacture the above-listed controlled
substances to make a supply of
marihuana available to the National
Institute of Drug Abuse (NIDA) for
distribution to research investigators in
support of the national research
program needs. No other activities for
these drug codes are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–17433 Filed 8–10–20; 8:45 am]
BILLING CODE P
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[NOTICE: (20–067)]
Drug Enforcement Administration
Name of Information Collection: NASA
Enterprise Salesforce COVID–19
Contact Tracing
[Docket No. DEA–693]
AGENCY:
Bulk Manufacturer of Controlled
Substances Application: National
Center for Natural Products Research
NIDA MPROJECT
SUMMARY:
DEPARTMENT OF JUSTICE
Drug Enforcement
Administration, Department of Justice.
ACTION: Notice of application.
AGENCY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 13, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on July 7, 2020, National
Center for Natural Products Research
National Institute of Drug Abuse (NIDA)
MPROJECT, University of Mississippi,
135 Coy Waller Complex, P.O. Box
1848, University, Mississippi 36877–
1848, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
DATES:
Controlled substance
Marijuana Extract ..........
PO 00000
Frm 00067
Fmt 4703
Drug
code
7350
Sfmt 4703
Schedule
I
National Aeronautics and
Space Administration (NASA).
ACTION: Notice of information collection.
The National Aeronautics and
Space Administration, as part of its
continuing effort to reduce paperwork
and respondent burden, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections.
DATES: Comments are due by Monday,
October 4, 2020.
ADDRESSES: All comments should be
addressed to Roger Kantz, National
Aeronautics and Space Administration,
300 E Street SW, Washington, DC
20546–0001.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information or
copies of the information collection
instrument(s) and instructions should
be directed to Roger Kantz, NASA
Clearance Officer, NASA Headquarters,
300 E Street SW, JF0000, Washington,
DC 20546, 281–792–7885 or email
Travis.Kantz@nasa.gov.
SUPPLEMENTARY INFORMATION:
I. Abstract
The information will be used to
determine whether NASA personnel
have been exposed to the COVID–19
virus and to track and trace their
interactions across the NASA
community for identifying possible
points of exposure.
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 85, Number 155 (Tuesday, August 11, 2020)]
[Notices]
[Page 48566]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17433]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-693]
Bulk Manufacturer of Controlled Substances Application: National
Center for Natural Products Research NIDA MPROJECT
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before October 13,
2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on July 7, 2020, National Center for Natural Products
Research National Institute of Drug Abuse (NIDA) MPROJECT, University
of Mississippi, 135 Coy Waller Complex, P.O. Box 1848, University,
Mississippi 36877-1848, applied to be registered as a bulk manufacturer
of the following basic class(es) of controlled substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marijuana Extract...................... 7350 I
Marijuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
------------------------------------------------------------------------
The company plans to bulk manufacture the above-listed controlled
substances to make a supply of marihuana available to the National
Institute of Drug Abuse (NIDA) for distribution to research
investigators in support of the national research program needs. No
other activities for these drug codes are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-17433 Filed 8-10-20; 8:45 am]
BILLING CODE P
